"WASHINGTON, DC â€” The Micra Transcatheter Pacing System by Medtronic has become the first leadless pacemaker system to be approved in the United States. The US Food and Drug Administration (FDA) announced the approval almost 2 months afte"...
There is currently no known treatment to reverse the effects of BRILINTA, and ticagrelor is not expected to be dialyzable. Treatment of overdose should follow local standard medical practice. Bleeding is the expected pharmacologic effect of overdosing. If bleeding occurs, appropriate supportive measures should be taken.
Platelet transfusion did not reverse the antiplatelet effect of BRILINTA in healthy volunteers and is unlikely to be of clinical benefit in patients with bleeding.
History Of Intracranial Hemorrhage
BRILINTA is contraindicated in patients with hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/11/2016
Additional Brilinta Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.